Skip to main content

Table 4 Univariate and Multivariate Survival Analysis

From: Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?

Variable

Univariate analysis

Multivariate analysis

P-value

HR (95% CI)

P-value

HR (95% CI)

Clinical stage

 T1-T2a

-

1.0 (reference)

-

-

 T2b-c

0.162

2.51 (0.69–9.16)

-

-

 T3a

0.227

2.23 (0.6–8.28)

-

-

 T3b-T4

0.045

3.91 (1.02–14.86)

0.138

1.33 (0.91–1.93)

Gleason score

 ≤ 6

-

1.0 (reference)

-

-

 7

0.223

3.65 (0.45–29.42)

-

-

 8–10

0.34

2.66 (0.35–19.87)

-

-

PSA

 <40

-

1.0 (reference)

-

-

 ≥40

<0.001

3.84 (1.82–8.080

0.001

3.75 (1.76–7.97)

>4 cores positive with Gleason 8–10

 ≤4

-

1.0 (reference)

-

-

 >4

0.032

2.27 (1.07–4.8)

0.23

1.41 (0.8–2.51)

 Unknown

0.635

0.6 (0.07–4.7)

-

-

Primary Gleason pattern

 <5

-

1.0 (reference)

-

-

 5

0.124

2.12 (0.81–5.55)

-

-

NCCN risk

 High risk

-

1.0 (reference)

-

-

 VHR

0.07

1.99 (0.94–4.23)

-

-

RT technique

 3D

-

1.0 (reference)

-

-

 IMRT

0.392

1.57 (0.55–4.41)

-

-

 VMAT

0.376

1.67 (0.53–5.22)

-

-